top of page

Revolutionizing Medicine with Cell-Based Therapies with Crystal Nyitray

Every day, we see technology improving the systems and industries all around us. From finance to environmental science and more, technological advances are allowing us to make great changes to the way we live and work. The medical field is no exception, with scientists and inventors working tirelessly to improve healthcare across the board. Crystal Nyitray, the CEO of Encellin, is here today to talk about how her company is changing the game by introducing cell-based therapies, allowing healthcare to become even more personal. This week’s episode 107 of How Women Inspire Podcast is about revolutionizing medicine with cell-based therapies! 



In this episode of How Women Inspire Podcast, Crystal Nyitray is sharing the importance of disruptive technology to improve our lives and actionable steps you can take right now to get involved with Encellin. 


Crystal Nyitray is the Founder and CEO of Encellin. She is an alumna of UCSF, Sanofi, and Y Combinator. She led Encellin’s over $5M seed raise, authored over 10 patents, and is an awardee of MedTech Innovator, Rosenman Innovators, and American Diabetes Innovator. 



Some of the talking points Julie and Crystal go over in this episode include:

  • The potential of encapsulated cell replacement therapy to revolutionize medicine.

  • How startups have the luxury of risk and can experiment with emerging technologies to benefit everyone.

  • Embracing inexperience as a strength and building networks from scratch.

  • How being comfortable with being different can lead to disruptive innovation and impactful change.


Thank you for listening! If you enjoyed this episode, take a screenshot of the episode to post in your stories and tag me!  And don’t forget to follow, rate, and review the podcast and tell me your key takeaways!


Learn more about How Women Inspire at https://www.howwomenlead.com/podcast 


CONNECT WITH CRYSTAL NYITRAY:


CONNECT WITH JULIE CASTRO ABRAMS:


43 views0 comments

Comments


bottom of page